Hide Board Information

Show Board Information

Kewaunee Scientific Corp. KEQU

Board Mod: Add me as mod

Asst Mods:

Last Post: 12/18/2023 2:50:48 PM

Board Marks: 0

Posts Today: 0

Board Views Today: 2

Kewaunee Scientific Corp. (NASDAQ: KEQU) Stock Message Board

1. KEQU Company Profile

    

2. KEQU Time & Sales

    

3. KEQU Recent News

    

4. KEQU Filings

    

5. KEQU Financials

    

6. KEQU Buy Rating

Create New Post View All Posts Board Mark Banned

Post

Subject

Author

Posted On

9	$KEQU News Article - Insiders Buying Chart	whytestocks	12/18/2023 2:50:48 PM
8	KEQU Stock year to date has changed +3.82%	Jake13	03/04/2015 3:00:15 AM
7	KEQU 18.48 Kewaunee Scientific Corp Stock Charts	chartguy89	03/04/2015 2:39:12 AM
6	KEQU Stock year to date has changed +2.02%	Jake13	02/26/2015 5:25:00 AM
5	KEQU 18.16 Kewaunee Scientific Corp Stock Charts	chartguy89	02/26/2015 4:41:33 AM
4	KEQU 18.70 Kewaunee Scientific Corp Stock Charts	chartguy89	12/04/2014 4:46:28 AM
3	Latest Kewaunee Scientific Corp (KEQU) Headlines	Stock_Tracker	03/13/2014 10:18:21 AM
2	KEQU Stock Charts Last: UNCH Saturday, March 1,	chartguy89	03/01/2014 7:02:24 PM
1	KEQU Stock Charts Last: -0.04 Friday, February	chartguy89	02/28/2014 12:03:45 AM

Recent Articles

• Copper Property CTL Trust Monthly Update for November 2025
• Elon Musk's Inspiring Advice for Aspiring Innovators
• Investigation of Major Mergers: A Look into Four Corporations
• How Chad IDE is Transforming Developer Productivity Today
• BexBack Unveils Exciting $100 Welcome Bonus for Traders
• Ray Dalio's Humble Beginnings: A Lesson in Resilience
• Lundbeck's Bexicaserin Shows Promise in Managing Childhood Epilepsies
• Lundbeck Unveils Positive Findings on Bexicaserin for Unique Epilepsies
• RadiantVibe Capital Unveils Insight Access Dashboard Initiative
• Kevin O'Leary's Formula for Financial Success: The $5M Rule
• Educators Unite for a Brighter Future at the Yidan Summit
• Elon Musk's Response to EU's $140 Million Penalty on X
• Copper Market Perspectives: Bullish Trends Amidst Contrasting Views
• Prelude Therapeutics Unveils Innovative MPN Treatment Breakthrough
• Current Trends in Cryptocurrency Markets: BTC, DOGE, ETH Updates
• Former MrBeast Creator Launches AI Platform for Content
• LiberNovo Launches Revolutionary Ergonomic Chair Globally
• LiberNovo Launches Omni Ergonomic Chair in European Market
• Blokees Unveils Exciting New Products at Major Comic Event
• Jensen Huang Reflects on Partnership with Elon Musk and Tesla
• Significant Progress in CLL Treatment with Lisaftoclax Insights
• New Findings on Lisaftoclax at ASH Annual Meeting 2025
• Marjorie Taylor Greene Opens Up About Trump and Political Rift
• Opportunity for Sprouts Farmers Market Investors Amid Legal Actions
• Labor Management Systems: A Pathway to Workforce Optimization
• Dave Ramsey Encourages Workers to Seek Fulfillment Elsewhere
• Perrigo Company Faces Class Action: Key Details for Investors
• Breakthrough CAR-T Therapy Shows Promise in Non-Hodgkin's Lymphoma
• CARVYKTI® Shows Promising Long-Term Remission Rates in Myeloma
• Exploring the Upcoming Boom in In-Memory Database Solutions
• System Infrastructure Software Market Expected to Surge by 2032
• Genmab's Epcoritamab Shows Promising Results in Trials
• Nurix Therapeutics Advances Bexobrutideg for CLL Patients
• Cogent Biosciences Unveils SUMMIT Study Insights on Bezuclastinib
• Class Action Lawsuit Filed Against Blue Owl Capital: Key Info
• Promising Phase 1 Results of Bexobrutideg for CLL Patients
• Cogent Biosciences Shares SUMMIT Trial Outcomes on Bezuclastinib
• Top 5 Trending Stocks: Insights on META, NFLX, and More
• CARVYKTI® Shows Promise in Long-Term Remission of Myeloma
• Concerns Rise Over ALT5 Sigma's Financial Stability and Audit Issues
• Education Leaders Unite for Change at Yidan Prize Summit 2025
• Projected Growth of Peptide Therapeutics Market by 2032
• Marex Stockholder Alert: Important Legal Deadline Approaching
• Comparative Analysis of MP Materials and USA Rare Earth Investment Prospects
• Viatris Sells Equity Stake in Biocon Biologics for $815 Million
• Important Information for StubHub Holdings, Inc. Investors
• Navigating 2026: JP Morgan's Insights on Economic Growth
• Deadline Approaches for aTyr Pharma Shareholders: Know Your Rights
• CBD Nutraceuticals Market Grows Rapidly, Expected to Hit $39B
• Transforming Hematology: clonoSEQ® Insights Fuel Progress